SCHEMBL23218641

SCHEMBL23218641

CCOC(=O)Cc1c(F)cccc1OCc1coc2ccc(Br)cc12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 4/20 0.39
ALOX5 P09917 3/20 0.38
MAPT P10636 3/20 0.36
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HTT P42858 1/20 0.35
THRB P10828 1/20 0.35
PTGFR P43088 1/20 0.35
EGFR P00533 1/20 0.35
MEN1 O00255 2/20 0.34
POLB P06746 2/20 0.34
KMT2A Q03164 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MTNR1A P48039 1/20 0.34
GAA P10253 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hexane SCHEMBL31615131 0.96 PTGER1 (0.37) PTGER1ALOX5MAPTNPSR1ALDH1A1
Hexane SCHEMBL23219247 0.96 PTGER1 (0.37) PTGER1ALOX5MAPTNPSR1ALDH1A1
SCHEMBL29852755 0.90 THRB (0.40) PTGER1ALOX5MAPTNPSR1ALDH1A1
SCHEMBL23218028 0.90 THRB (0.40) PTGER1ALOX5MAPTNPSR1ALDH1A1
SCHEMBL29852971 0.90 KMT2A (0.40) PTGER1MAPTNPSR1ALDH1A1HTT
SCHEMBL23218215 0.90 KMT2A (0.40) PTGER1MAPTNPSR1ALDH1A1HTT
SCHEMBL29853198 0.86 ALOX5 (0.38) ALOX5MAPTALDH1A1HTTTHRB
SCHEMBL23218199 0.86 ALOX5 (0.38) ALOX5MAPTALDH1A1HTTTHRB
SCHEMBL23218949 0.85 TBXAS1 (0.41) PTGER1MAPTNPSR1ALDH1A1HTT
SCHEMBL23218535 0.85 PTGER1 (0.39) PTGER1ALOX5MAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PTGER1 1339/4885ALOX5 317/4885MAPT 4793/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PTGER1 1089/4885ALOX5 260/4885MAPT 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.